Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celldex Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing antibody-based therapeutics in immunology and mast cell-mediated disease. Its 8-K reports furnish financial results and corporate updates, including clinical and regulatory disclosures for barzolvolimab programs and other pipeline candidates, as well as material-event and capital-structure disclosures related to common stock financing.
Proxy materials describe annual stockholder voting matters, director elections, auditor ratification, executive compensation and equity incentive plan proposals. The filing record also identifies Celldex common stock, par value $.001, trading under CLDX on the Nasdaq Capital Market.
Celldex Therapeutics director James J. Marino received a grant of stock options as part of his equity compensation. He was awarded non-qualified options covering 26,000 shares of Common Stock, with an exercise price of $34.09 per share. The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan, carry no upfront cost to Marino, and are exercisable beginning on June 25, 2027. These options are scheduled to expire on June 25, 2036 if not exercised. After this grant, Marino holds options on 26,000 shares according to this filing.
Celldex Therapeutics director Herbert J. Conrad received an option grant for 26,000 shares of common stock. The non-qualified stock option has an exercise price of $34.09 per share and expires on June 25, 2036. This award, granted under the company’s 2021 Omnibus Equity Incentive Plan, brings his reported option holdings to 26,000 derivative shares.
Celldex Therapeutics, Inc. director Harry Jr Penner reported receiving a grant of non-qualified stock options. The award covers 26,000 options to buy Celldex common stock at an exercise price of $34.09 per share, expiring on June 25, 2036. The options, issued at no cost to the director, were granted under the company’s 2021 Omnibus Equity Incentive Plan and leave him holding 26,000 derivative securities following the transaction. This is a compensation-related grant rather than an open-market share purchase or sale.
Celldex Therapeutics, Inc. reported results from its 2026 annual stockholder meeting, including approval of an amendment to its 2021 Omnibus Equity Incentive Plan. Stockholders increased the shares available for issuance under the plan by 3,400,000, bringing the total reserve to 12,900,000 shares and clarified tax withholding terms for awards.
All director nominees were elected with more than 59 million votes cast in favor for each seat. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 and approved, on an advisory, non-binding basis, the compensation of named executive officers.
Celldex Therapeutics reports amended Schedule 13G ownership filing by Kynam Capital. The amendment states 5,840,567 shares of Common Stock are beneficially owned, representing 8.77% of the class. The filing lists shared voting and dispositive power of 5,840,567 shares and is signed by Yue Tang.
The filing names Kynam Capital Management, LP; Kynam Capital Management GP, LLC; and Yue Tang and gives principal addresses for the filer and issuer.
Celldex Therapeutics, Inc. ownership disclosure: Bellevue Group and its wholly owned subsidiary Bellevue Asset Management AG report beneficial ownership of 1,200,000 shares of Common Stock, representing 1.5% of Common Stock deemed outstanding (based on 78,492,072 shares). This Amendment No. 1 is described as an exit filing because the reporting persons now own less than five percent.
State Street Corporation reports beneficial ownership of 2,804,168 shares (4.2%) of CELLDex Therapeutics common stock. The filing shows shared voting power of 2,620,053 shares and shared dispositive power over 2,804,168 shares. The Schedule 13G lists affiliated investment adviser entities as holders.
Celldex Therapeutics reported a larger quarterly loss as it accelerates late-stage development of its lead antibody barzolvolimab. For the three months ended March 31, 2026, revenue was $15 thousand while research and development expenses rose to $73.0 million, driving a net loss of $78.7 million.
Cash, cash equivalents and marketable securities totaled $451.5 million at March 31, 2026, and an April 2026 underwritten offering added about $323.9 million of net proceeds. Management believes these resources can fund current planned operations through 2028 while Phase 3 urticaria trials and Phase 2 programs in prurigo nodularis and atopic dermatitis progress.
Celldex Therapeutics reported a larger net loss for the first quarter of 2026 as it accelerated investment in its late-stage pipeline and strengthened its balance sheet. Net loss was $78.7 million, or ($1.18) per share, compared to $53.8 million, or ($0.81), a year earlier, driven mainly by higher barzolvolimab clinical and manufacturing costs.
Cash, cash equivalents and marketable securities were $451.5 million as of March 31, 2026. In April, Celldex closed a follow-on underwritten public offering of 11,896,750 shares, generating $345.0 million in gross proceeds and approximately $323.9 million in net proceeds, which management believes will fund operations through 2028.
Operationally, enrollment in the Phase 3 chronic spontaneous urticaria barzolvolimab program (EMBARQ-CSU1 and CSU2) was completed six months ahead of guidance, with 1,939 patients enrolled across 43 countries. Multiple additional barzolvolimab Phase 2 and 3 studies, and the CDX-622 bispecific program, are progressing with several data readouts expected in 2026 and a planned BLA filing for barzolvolimab in 2027.
FMR LLC amended its Schedule 13G/A to report beneficial ownership of 3,749,048.03 shares of CellDex Therapeutics common stock, representing 5.6% of the class.
The filing names FMR LLC as the reporting person with sole dispositive power for 3,749,048.03 shares and lists Abigail P. Johnson as having shared filing authority; signatures reference a Power of Attorney effective April 13, 2026. The exhibit list includes a 13d-1(k)(1) agreement and a referenced Exhibit 24.